Along with side effects, another challenge is represented by the ability of cancer cells to rewire metabolic pathways when exposed to precision therapies, leading to resistance, as shown, for example, by FLT3 leukaemia-initiating cells (LICs) in AML when exposed to venetoclax–azacitidine treatment [244], which increased FAO to maintain OXPHOS upon amino acid loss. This evidence concerns the gene FLT3 and cancer.